Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XAYNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DJ.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XAENUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.467NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.484NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.476NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
A.19NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
A.18NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.404NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CV.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DJ.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.73NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DW.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BR.5.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.75.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XAKNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XAANUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.42.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.348NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.428.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AJ.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.459NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.160.29NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.415.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.243.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.98NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.566NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.480NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.579NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
N.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
P.1.11 (Gamma)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.435NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.445NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.124NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.384NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XAQNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.3.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.569NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.524NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
A.23NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.596.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.473NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.595.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.76.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.38.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.38.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BM.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.15.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.2.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.16.32NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used